Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Icecure Medical Ltd Ord (ICCM)

Icecure Medical Ltd Ord (ICCM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation PR Newswire - Tue Jul 14, 7:32AM CDT

CAESAREA, Israel , July 14, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive liquid nitrogen-based cryoablation...

ICCM : 3.00 (-7.12%)
IceCure Highlights Expanding Commercial Adoption of ProSenseâ„¢ Cryoablation in Brazil Following FDA Clearance for Breast Cancer PR Newswire - Mon Jul 6, 7:11AM CDT

Growing physician interest and commercial adoption for ProSenseâ„¢ in Brazil's expanding interventional oncology markets increased following FDA authorization

ICCM : 3.00 (-7.12%)
IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement PR Newswire - Thu Jun 25, 7:12AM CDT

CAESAREA, Israel , June 25, 2026 /PRNewswire/ --  IceCure Medical Ltd.  (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology...

ICCM : 3.00 (-7.12%)
IceCure Highlights New Peer-Reviewed Journal Article in Leading Surgery Journal, Demonstrating Cryoablation's Advantages Over Radiofrequency Ablation for Early-Stage Breast Cancer PR Newswire - Tue Jun 23, 7:10AM CDT

Published in the International Journal of Surgery, globally ranked in the top three among surgery journals ,  the article highlights strong clinical outcomes with ProSense® cryoablation and describes...

ICCM : 3.00 (-7.12%)
IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investor PR Newswire - Wed Jun 17, 12:14PM CDT

CAESAREA, Israel , June 17, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...

ICCM : 3.00 (-7.12%)
IceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA Clearance PR Newswire - Wed Jun 17, 7:25AM CDT

Increase driven by FDA clearance, clinical guideline support, and increased physician demand. Significant rise in number of leads for ProSense® systems generated at U.S. medical society conferences compared...

ICCM : 3.00 (-7.12%)
IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance PR Newswire - Tue Jun 2, 7:30AM CDT

Proactive Step to Regain Nasdaq Compliance as Part of the Company's Broader Capital Markets Strategy

ICCM : 3.00 (-7.12%)
IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked PR Newswire - Tue May 19, 7:30AM CDT

At the annual European Conference on Interventional Oncology, ICESECRET data presented demonstrated 89.4% recurrence-free rate in patients with tumors ≤3 cm and 83.9% of patients remained recurrence-free...

ICCM : 3.00 (-7.12%)
IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement PR Newswire - Wed May 13, 3:30PM CDT

No Immediate Effect on Nasdaq Listing or Trading of the Company's Ordinary Shares

ICCM : 3.00 (-7.12%)
IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America PR Newswire - Tue May 12, 7:30AM CDT

Pent-up demand immediately following FDA clearance generates 46% increase in active customer accounts using ProSense® as of the end of the first quarter 2026, compared with prior to FDA clearance

ICCM : 3.00 (-7.12%)

Barchart Exclusives

Before You Chase SMCI’s SpaceX Rally, Remember This Rocket Has Misfired Before Barchart - 35 minutes ago
Investors should wait for the upcoming earnings report before jumping in on the margin improvement and SpaceX hype. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.